In line with these findings, we additionally observed that SATB2-low/absent CRCs were able to identify patients with a poor prognosis in both CDX2 expression groups (CDX2-low/absent vs. CDX2- high), while CDX2 showed no prognostic relevance in SATB2 expression subgroups, rendering SATB2 as the prognostically superior immunohistochemical biomarker in CRC compared to CDX2. This evidence concerns the gene CDX2 and colorectal carcinoma.